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SUMMARY
Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of 
depression and related disorders. The ability to promote both structural and functional plasticity in 
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the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the 
dissociative anesthetic ketamine. Here, we report that, like ketamine, serotonergic psychedelics are 
capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo. These 
changes in neuronal structure are accompanied by increased synapse number and function, as 
measured by fluorescence microscopy and electrophysiology. The structural changes induced by 
psychedelics appear to result from stimulation of the TrkB, mTOR, and 5-HT2A signaling 
pathways and could possibly explain the clinical effectiveness of these compounds. Our results 
underscore the therapeutic potential of psychedelics and, importantly, identify several lead 
scaffolds for medicinal chemistry efforts focused on developing plasticity-promoting compounds 
as safe, effective, and fast-acting treatments for depression and related disorders.
In Brief
Ly et al. demonstrate that psychedelic compounds such as LSD, DMT, and DOI increase dendritic 
arbor complexity, promote dendritic spine growth, and stimulate synapse formation. These cellular 
effects are similar to those produced by the fast-acting antidepressant ketamine and highlight the 
potential of psychedelics for treating depression and related disorders.
INTRODUCTION
Neuropsychiatric diseases, including mood and anxiety disorders, are some of the leading 
causes of disability worldwide and place an enormous economic burden on society 
(Gustavsson et al., 2011; Whiteford et al., 2013). Approximately one-third of patients will 
not respond to current antidepressant drugs, and those who do will usually require at least 2–
4 weeks of treatment before they experience any beneficial effects (Rush et al., 2006). 
Depression, post-traumatic stress disorder (PTSD), and addiction share common neural 
circuitry (Arnsten, 2009; Russo et al., 2009; Peters et al., 2010; Russo and Nestler, 2013) 
and have high comorbidity (Kelly and Daley, 2013). A preponderance of evidence from a 
combination of human imaging, postmortem studies, and animal models suggests that 
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atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of 
depression and related disorders and is precipitated and/or exacerbated by stress (Arnsten, 
2009; Autry and Monteggia, 2012; Christoffel et al., 2011; Duman and Aghajanian, 2012; 
Duman et al., 2016; Izquierdo et al., 2006; Pittenger and Duman, 2008; Qiao et al., 2016; 
Russo and Nestler, 2013). These structural changes, such as the retraction of neurites, loss of 
dendritic spines, and elimination of synapses, can potentially be counteracted by compounds 
capable of promoting structural and functional neural plasticity in the PFC (Castrén and 
Antila, 2017; Cramer et al., 2011; Duman, 2002; Hayley and Litteljohn, 2013; Kolb and 
Muhammad, 2014; Krystal et al., 2009; Mathew et al., 2008), providing a general solution to 
treating all of these related diseases. However, only a relatively small number of compounds 
capable of promoting plasticity in the PFC have been identified so far, each with significant 
drawbacks (Castrén and Antila, 2017). Of these, the dissociative anesthetic ketamine has 
shown the most promise, revitalizing the field of molecular psychiatry in recent years.
Ketamine has demonstrated remarkable clinical potential as a fast-acting antidepressant 
(Berman et al., 2000; Ionescu et al., 2016; Zarate et al., 2012), even exhibiting efficacy in 
treatment-resistant populations (DiazGranados et al., 2010; Murrough et al., 2013; Zarate et 
al., 2006). Additionally, it has shown promise for treating PTSD (Feder et al., 2014) and 
heroin addiction (Krupitsky et al., 2002). Animal models suggest that its therapeutic effects 
stem from its ability to promote the growth of dendritic spines, increase the synthesis of 
synaptic proteins, and strengthen synaptic responses (Autry et al., 2011; Browne and Lucki, 
2013; Li et al., 2010).
Like ketamine, serotonergic psychedelics and entactogens have demonstrated rapid and 
long-lasting antidepressant and anxiolytic effects in the clinic after a single dose (Bouso et 
al., 2008; Carhart-Harris and Goodwin, 2017; Grob et al., 2011; Mithoefer et al., 2013, 
2016; Nichols et al., 2017; Sanches et al., 2016; Osório et al., 2015), including in treatment-
resistant populations (Carhart-Harris et al., 2016, 2017; Mithoefer et al., 2011; Oehen et al., 
2013; Rucker et al., 2016). In fact, there have been numerous clinical trials in the past 30 
years examining the therapeutic effects of these drugs (Dos Santos et al., 2016), with 3,4-
methylenedioxymethamphetamine (MDMA) recently receiving the “breakthrough therapy” 
designation by the Food and Drug Administration for treating PTSD. Furthermore, classical 
psychedelics and entactogens produce antidepressant and anxiolytic responses in rodent 
behavioral tests, such as the forced swim test (Cameron et al., 2018) and fear extinction 
learning (Cameron et al., 2018; Catlow et al., 2013; Young et al., 2015), paradigms for 
which ketamine has also been shown to be effective (Autry et al., 2011; Girgenti et al., 2017; 
Li et al., 2010). Despite the promising antidepressant, anxiolytic, and anti-addictive 
properties of serotonergic psychedelics, their therapeutic mechanism of action remains 
poorly understood, and concerns about safety have severely limited their clinical usefulness.
Because of the similarities between classical serotonergic psychedelics and ketamine in both 
preclinical models and clinical studies, we reasoned that their therapeutic effects might 
result from a shared ability to promote structural and functional neural plasticity in cortical 
neurons. Here, we report that serotonergic psychedelics and entactogens from a variety of 
chemical classes (e.g., amphetamine, tryptamine, and ergoline) display plasticity-promoting 
properties comparable to or greater than ketamine. Like ketamine, these compounds 
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stimulate structural plasticity by activating the mammalian target of rapamycin (mTOR). To 
classify the growing number of compounds capable of rapidly promoting induced plasticity 
(Castrén and Antila, 2017), we introduce the term “psychoplastogen, ” from the Greek roots 
psych- (mind), -plast (molded), and -gen (producing). Our work strengthens the growing 
body of literature indicating that psychoplastogens capable of promoting plasticity in the 
PFC might have value as fast-acting antidepressants and anxiolytics with efficacy in 
treatment-resistant populations and suggests that it may be possible to use classical 
psychedelics as lead structures for identifying safer alternatives.
RESULTS
Psychedelics Promote Neuritogenesis
Because atrophy of cortical neurons is believed to be a contributing factor to the 
development of mood and anxiety disorders (Christoffel et al., 2011; Duman and 
Aghajanian, 2012), we first treated cultured cortical neurons with psychedelics from a 
variety of structural classes (Figures 1A and S1A) and measured the resulting changes in 
various morphological features. Using Sholl analysis (Ristanovic et al., 2006), we observed 
that several psychedelics increased dendritic arbor complexity comparably to ketamine, as 
measured by the area under the curve of the Sholl plots as well as the maximum number of 
crossings (Figures 1B–1E and S1B–S1E). This increase in arbor complexity appeared to 
result from large changes in both the number of dendritic branches and the total length of the 
arbors (Figures 1F, 1H, S1F, and S1H). Psychedelics had a limited effect on the number of 
primary dendrites and did not alter the length of the longest dendrite (Figures 1G, 1I, S1G, 
and S1I).
Nearly all psychedelic compounds tested were capable of robustly promoting neuritogenesis, 
with comparable effects being produced by tryptamines (N,N-dimethyltryptamine [DMT] 
and psilocin), amphetamines (2,5-dimethoxy-4-iodoamphetamine [DOI] and MDMA), and 
ergolines (lysergic acid diethylamide [LSD]). As a positive control, we treated cells with 
7,8-dihydroxyflavone (DHF), a psychoplastogen structurally dissimilar to classical 
psychedelics (Jang et al., 2010), and found that it also increased dendritic arbor complexity 
(Figure S2). This neurite outgrowth structural phenotype seems to only be induced by select 
compounds because serotonin and D-amphetamine, molecules that are chemically related to 
classical psychedelics and entactogens, exerted minimal to no effects on neuritogenesis 
(Figure S2).
To establish the relative potencies and efficacies of hallucinogens and entactogens for 
promoting neurite outgrowth, we conducted 8-point dose-response studies (Figure S3). We 
defined 100% and 0% efficacy as the maximum number of crossings induced by ketamine 
(10 μM) and vehicle (0.1% DMSO), respectively. We chose the 10 μM concentration of 
ketamine as the upper limit because this concentration of ketamine is reached in the brain 
following intraperitoneal administration of an antidepressant dose in rats (Yang et al., 2018). 
For consistency, we used this same concentration when testing the effects of psychedelics 
and entactogens, with DMT being the only exception. We used a maximum 90 μM 
concentration of DMT in our studies to more closely mimic the brain concentration of DMT 
in rats treated with an antidepressant dose (Cohen and Vogel, 1972; Cameron et al., 2018). 
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In this neuritogenesis assay, ketamine’s half maximal effective concentration (EC50) value 
was 132 nM. Surprisingly, the majority of the psychedelics and entactogens we tested 
exhibited significantly greater potency than ketamine, with LSD being particularly potent 
(EC50 = 0.409 nM). In fact, LSD exhibited activity across 8 orders of magnitude into the low 
picomolar range (Figure S3).
Notably, the anti-addictive alkaloid ibogaine (Alper, 2001; Belgers et al., 2016) was the only 
psychedelic tested that had absolutely no effect (Figure S4). This was a surprising result 
because we hypothesized that ibogaine’s long-lasting anti-addictive properties might result 
from its psychoplastogenic properties. Previous work by He et al. (2005) clearly 
demonstrated that ibogaine increases the expression of glial cell line-derived neurotrophic 
factor (GDNF) and that this plasticity-promoting protein is critical to ibogaine’s anti-
addictive mechanism of action. Because several reports have suggested that noribogaine, a 
metabolite of ibogaine, might actually be the active compound in vivo (Zubaran et al., 1999; 
Baumann et al., 2000, 2001), we decided to test its ability to promote neuritogenesis in 
cultured cortical neurons. Gratifyingly, noribogaine robustly increased dendritic arbor 
complexity with an EC50 value comparable to ketamine (Figure S3), providing additional 
evidence suggesting that it may be the active compound in vivo.
To assess the in vivo effects of classical psychedelics on neuritogenesis, we started treating 
Drosophila larvae during the first instar with LSD and DOI. As observed in rodent cortical 
cultures, both LSD and DOI significantly increased dendritic branching of class I sensory 
neurons; however, they did not increase the total length of the dendritic arbors (Figures 1J–
1L). Because of the striking effects of psychedelics on the structures of immature neurons, 
we hypothesized that they might influence neurodevelopment. To test this, we chronically 
treated zebrafish embryos with compounds for 6 days immediately following dechorionation 
and assessed gross morphological changes and behavior. We did not observe any differences 
in head sizes between the treatment groups, nor did we detect any statistically significant 
differences in activity levels (Figure S5). Next we assessed the ability of psychedelics to 
promote neuritogenesis in more mature neurons by starting to treat Drosophila larvae during 
the late second instar. Again, psychedelics increased the branching of class I neurons, 
although the effect was less dramatic than that observed when treatment was started during 
the first instar (Figure 1M–1O). Although different developmental stages might be more or 
less susceptible to the effects of psychedelics, it is also possible that the smaller effect size 
observed after administering compounds starting at the later time point was simply the result 
of treating the larvae for a shorter period of time. Regardless, it was quite surprising to 
observe compound-induced changes in neuronal structure after initiating treatment during 
the late second instar because class I neurons are stereotyped and typically possess relatively 
few higher-order branches (Grueber et al., 2002). Moreover, our results demonstrate that 
psychedelics can promote changes in neuronal structure across vertebrate (rats) and 
invertebrate (Drosophila) species, suggesting that they act through an evolutionarily 
conserved mechanism.
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Psychedelics Promote Spinogenesis and Synaptogenesis
In addition to dendritic atrophy, loss of dendritic spines is a hallmark of depression and other 
neuropsychiatric disorders (Christoffel et al., 2011; Duman and Aghajanian, 2012), so we 
next assessed the effects of psychedelics on spinogenesis. We treated mature rat cortical 
cultures for 24 hr with DOI, DMT, and LSD as representative compounds from the 
amphetamine, tryptamine, and ergoline classes of psychedelics, respectively. All three 
compounds increased the number of dendritic spines per unit length, as measured by super-
resolution structured illumination microscopy (SIM) (Figures 2A, 2B, and S6), with LSD 
nearly doubling the number of spines per 10 μm. Additionally, treatment caused a shift in 
spine morphology, favoring immature (thin and filopodium) over more mature (mushroom) 
spine types (Figure 2C). Colocalization of pre- and postsynaptic markers following 
treatment demonstrated that psychedelics promoted synaptogenesis by increasing the 
density, but not the size of synapses (Figure 2D–2F). This increase in synapse density was 
accompanied by an increase in the density of VGLUT1 puncta, but not PSD-95 puncta, 
following compound administration (Figures 2G and 2H).
Encouraged by our in vitro results, we next assessed the effects of a single intraperitoneal 
dose of DMT on spinogenesis in the PFC of adult rats using Golgi-Cox staining. We chose 
to administer a 10 mg/kg dose of DMT for three reasons. First, all available data suggested 
that this dose would produce hallucinogenic effects in rats with minimal safety risks 
(Glennon et al., 1980, 1983; Glennon, 1999; Gatch et al., 2009; Smith et al., 1998; Appel et 
al., 1999; Winter et al., 2007; Carbonaro et al., 2015; Helsley et al., 1998; Strassman et al., 
1994; Nair and Jacob, 2016). Second, we have previously shown that a 10 mg/kg dose of 
DMT produces positive effects in rat behavioral tests relevant to depression and PTSD 
(Cameron et al., 2018). Finally, we wanted to directly compare the effects of DMT with 
ketamine, and seminal studies conducted by Li et al. (2010) had previously demonstrated 
that a 10 mg/kg dose of ketamine produced a robust increase in dendritic spine density in the 
PFC of rats. We observed a significant increase in the density of dendritic spines on cortical 
pyramidal neurons 24 hr after dosing with DMT (Figures 2I and 2J). This effect was 
comparable with that produced by ketamine at the same dose (Figure 2J). Importantly, this 
DMT-induced increase in dendritic spine density was accompanied by functional effects. Ex 
vivo slice recordings revealed that both the frequency and amplitude of spontaneous 
excitatory postsynaptic currents (EPSCs) were increased following DMT treatment (Figures 
2K–2M). Interestingly, 10 mg/kg and 1 mg/kg doses produced similar responses despite the 
fact that they are predicted to be hallucinogenic and subhallucinogenic, respectively 
(Strassman et al., 1994; Nair and Jacob, 2016).
Because the half-life of DMT is exceedingly short (~15 min), these results confirm that 
structural and functional changes induced by DMT persist for hours after the compound has 
been cleared from the body. Moreover, they demonstrate that DMT produces functional 
effects on pyramidal neurons of the PFC that mirror those produced by ketamine (Li et al., 
2010). Because the PFC is a key brain region involved in extinction learning (Quirk et al., 
2006), and both ketamine and DMT have been shown to facilitate fear extinction (Cameron 
et al., 2018; Girgenti et al., 2017), our results suggest a link between the plasticity-
promoting and behavioral effects of these drugs. Because fear extinction can be enhanced by 
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increasing levels of brain-derived neurotrophic factor (BDNF) in the PFC (Peters et al., 
2010), and ketamine’s behavioral effects have been shown to be BDNF-dependent (Lepack 
et al., 2014), we next sought to determine the role of BDNF signaling in the plasticity-
promoting effects of classical psychedelics.
Psychedelics Promote Plasticity through a TrkB-and mTOR-Dependent Mechanism
The role of BDNF in both neuritogenesis and spinogenesis is well known (Cohen-Cory et 
al., 2010), and several reports suggest that psychedelics are capable of increasing levels of 
neurotrophic factors (He et al., 2005; Martin et al., 2014; Nichols and Sanders-Bush, 2002; 
Vaidya et al., 1997). Therefore, we treated cortical neurons with BDNF, DOI, and a 
combination of the two to see whether they had any additive or synergistic effects. Dose-
response studies using recombinant BDNF (Figures 3A–3C) revealed that a 50 ng/mL 
treatment increased neuritogenesis to a comparable extent as DOI (10 μM). Moreover, a 
combination of the two did not confer any added benefit, suggesting that they operate 
through a related mechanism (Figures 3D–3F). Next, we treated cortical neurons with DOI, 
DMT, and LSD for 24 hr before measuring BDNF gene and protein expression using droplet 
digital PCR (ddPCR) and ELISA, respectively. Although psychedelics did not increase the 
expression of BDNF transcript (Figure 3G), they did result in a 2-fold increase in BDNF 
protein levels, although this effect was not statistically significant (Figure 3H). When 
cortical cultures were co-treated with ANA-12 (Cazorla et al., 2011), a selective antagonist 
of BDNF’s high-affinity receptor TrkB, the ability of psychedelics or BDNF to stimulate 
neuritogenesis and spinogenesis was completely blocked (Figure 4).
Activation of TrkB is known to promote signaling through mTOR (Takei et al., 2004), which 
plays a key role in structural plasticity (Jaworski et al., 2005; Kumar et al., 2005), the 
production of proteins necessary for synaptogenesis (Hoeffer and Klann, 2010), and the 
effects of ketamine (Dwyer and Duman, 2013; Li et al., 2010). Treatment with rapamycin, 
an mTOR inhibitor, completely blocked psychedelic-induced neuritogenesis (Figure 5), thus 
confirming that mTOR activation plays a role in the plasticity-promoting effects of classical 
serotonergic psychedelics.
The 5-HT2A Receptor Mediates the Effects of Psychedelics on Structural Plasticity
Finally, we sought to determine whether the 5-HT2A receptor played any role in the 
plasticity-promoting effects of DOI, DMT, and LSD because this receptor is known to be 
primarily responsible for the hallucinogenic effects of classical psychedelics (Nichols, 2004, 
2016). Furthermore, the psychoplastogenic potencies of these and related compounds 
correlate well with their 5-HT2A receptor affinities (Figure S3) (i.e., a higher 5-HT2A 
binding affinity generally predicts more potent psychoplastogenic effects). Control 
experiments demonstrated that 5-HT2A receptors were expressed on cultured rat cortical 
neurons at both 6 days in vitro (DIV6) and DIV19 (Figure 6A). Next we found that co-
treatment with ketanserin, a selective 5-HT2A antagonist, completely abrogated the ability 
of DMT, LSD, and DOI to promote both neuritogenesis and spinogenesis (Figures 6B–6F). 
Ketanserin was also able to block the effects of psilocin as well as the non-classical 
psychedelic noribogaine and enactogen MDMA (Figure 6G).
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These initial experiments were performed using doses of psychoplastogens that produced 
maximal effects on structural plasticity (circa 10 μM) in combination with a 10-fold excess 
of ketanserin (100 μM). At these concentrations, we could not rule out the possibility of 
other receptors contributing to the antagonistic effects of ketanserin. Therefore, we treated 
cultured cortical neurons with a significantly lower dose of LSD (10 nM) and attempted to 
block its ability to promote neurite outgrowth using increasing doses of ketanserin (Figure 
6H). We found that ketanserin blocks the psychoplastogenic effects of LSD by ~50% when 
treated at 10 nM. This is consistent with the fact that the binding affinities of ketanserin and 
LSD for the 5-HT2A receptor are roughly equivalent (low nanomolar). Increasing the 
concentration of ketanserin to 100 nM, 10-fold higher than the concentration of LSD used in 
this experiment, completely prevented LSD-induced neuritogenesis. At 100 nM, ketanserin 
is relatively selective for the 5-HT2A receptor, although, at this concentration, we cannot 
rule out the possible involvement of 5-HT2C, adrenergic, or histamine receptors.
As a final note, the concentration responses of most psychoplastogens had Hill slopes that 
deviated from 1.0 (Figure S3), implying polypharmacology. Because psychedelics have 
relatively high affinities for 5-HT2A receptors, it is likely that the effects of psychedelics are 
mediated primarily through 5-HT2A receptors at low concentrations and modulated by other 
targets at high concentrations. Interestingly, the concentration response of DMT was the 
only one to exhibit a Hill slope greater than 1.0, indicating some form of cooperativity.
DISCUSSION
Classical serotonergic psychedelics are known to cause changes in mood (Griffiths et al., 
2006, 2008, 2011) and brain function (Carhart-Harris et al., 2017) that persist long after the 
acute effects of the drugs have subsided. Moreover, several psychedelics elevate glutamate 
levels in the cortex (Nichols, 2004, 2016) and increase gene expression in vivo of the 
neurotrophin BDNF as well as immediate-early genes associated with plasticity (Martin et 
al., 2014; Nichols and Sanders-Bush, 2002; Vaidya et al., 1997). This indirect evidence has 
led to the reasonable hypothesis that psychedelics promote structural and functional neural 
plasticity, although this assumption had never been rigorously tested (Bogenschutz and 
Pommy, 2012; Vollenweider and Kometer, 2010). The data presented here provide direct 
evidence for this hypothesis, demonstrating that psychedelics cause both structural and 
functional changes in cortical neurons.
Prior to this study, two reports suggested that psychedelics might be able to produce changes 
in neuronal structure. Jones et al. (2009) demonstrated that DOI was capable of transiently 
increasing the size of dendritic spines on cortical neurons, but no change in spine density 
was observed. The second study showed that DOI promoted neurite extension in a cell line 
of neuronal lineage (Marinova et al., 2017). Both of these reports utilized DOI, a 
psychedelic of the amphetamine class. Here we demonstrate that the ability to change 
neuronal structure is not a unique property of amphetamines like DOI because psychedelics 
from the ergo-line, tryptamine, and iboga classes of compounds also promote structural 
plasticity. Additionally, D-amphetamine does not increase the complexity of cortical 
dendritic arbors in culture, and therefore, these morphological changes cannot be simply 
attributed to an increase in monoamine neurotransmission.
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The identification of psychoplastogens belonging to distinct chemical families is an 
important aspect of this work because it suggests that ketamine is not unique in its ability to 
promote structural and functional plasticity. In addition to ketamine, the prototypical 
psychoplastogen, only a relatively small number of plasticity-promoting small molecules 
have been identified previously. Such compounds include the N-methyl-D-aspartate 
(NMDA) receptor ligand GLYX-13 (i.e., rapastinel), the mGlu2/3 antagonist LY341495, the 
TrkB agonist 7,8-DHF, and the muscarinic receptor antagonist scopolamine (Lepack et al., 
2016; Castello et al., 2014; Zeng et al., 2012; Voleti et al., 2013). We observe that 
hallucinogens from four distinct structural classes (i.e., tryptamine, amphetamine, ergoline, 
and iboga) are also potent psychoplastogens, providing additional lead scaffolds for 
medicinal chemistry efforts aimed at identifying neurotherapeutics. Furthermore, our 
cellular assays revealed that several of these compounds were more efficacious (e.g., 
MDMA) or more potent (e.g., LSD) than ketamine. In fact, the plasticity-promoting 
properties of psychedelics and entactogens rivaled that of BDNF (Figures 3A–3C and S3). 
The extreme potency of LSD in particular might be due to slow off kinetics, as recently 
proposed following the disclosure of the LSD-bound 5-HT2B crystal structure (Wacker et 
al., 2017).
Importantly, the psychoplastogenic effects of psychedelics in cortical cultures were also 
observed in vivo using both vertebrate and invertebrate models, demonstrating that they act 
through an evolutionarily conserved mechanism. Furthermore, the concentrations of 
psychedelics utilized in our in vitro cell culture assays were consistent with those reached in 
the brain following systemic administration of therapeutic doses in rodents (Yang et al., 
2018; Cohen and Vogel, 1972). This suggests that neuritogenesis, spinogenesis, and/or 
synaptogenesis assays performed using cortical cultures might have value for identifying 
psychoplastogens and fast-acting antidepressants. It should be noted that our structural 
plasticity studies performed in vitro utilized neurons exposed to psychedelics for extended 
periods of time. Because brain exposure to these compounds is often of short duration due to 
rapid metabolism, it will be interesting to assess the kinetics of psychedelic-induced 
plasticity.
A key question in the field of psychedelic medicine has been whether or not psychedelics 
promote changes in the density of dendritic spines (Kyzar et al., 2017). Using super-
resolution SIM, we clearly demonstrate that psychedelics do, in fact, increase the density of 
dendritic spines on cortical neurons, an effect that is not restricted to a particular structural 
class of compounds. Using DMT, we verified that cortical neuron spine density increases in 
vivo and that these changes in structural plasticity are accompanied by functional effects 
such as increased amplitude and frequency of spontaneous EPSCs. We specifically designed 
these experiments to mimic previous studies of ketamine (Li et al., 2010) so that we might 
directly compare these two compounds, and, to a first approximation, they appear to be 
remarkably similar. Not only do they both increase spine density and neuronal excitability in 
the cortex, they seem to have similar behavioral effects. We have shown previously that, like 
ketamine, DMT promotes fear extinction learning and has antidepressant effects in the 
forced swim test (Cameron et al., 2018). These results, coupled with the fact that ayahuasca, 
a DMT-containing concoction, has potent antidepressant effects in humans (Osório et al., 
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2015; Sanches et al., 2016; Santos et al., 2007), suggests that classical psychedelics and 
ketamine might share a related therapeutic mechanism.
Although the molecular targets of ketamine and psychedelics are different (NMDA and 5-
HT2A receptors, respectively), they appear to cause similar downstream effects on structural 
plasticity by activating mTOR. This finding is significant because ketamine is known to be 
addictive whereas many classical psychedelics are not (Nutt et al., 2007, 2010). The exact 
mechanisms by which these compounds stimulate mTOR is still not entirely understood, but 
our data suggest that, at least for classical psychedelics, TrkB and 5-HT2A receptors are 
involved. Although most classical psychedelics are not considered to be addictive, there are 
still significant safety concerns with their use in medicine because they cause profound 
perceptual disturbances and still have the potential to be abused. Therefore, the identification 
of non-hallucinogenic analogs capable of promoting plasticity in the PFC could facilitate a 
paradigm shift in our approach to treating neuropsychiatric diseases. Moreover, such 
compounds could be critical to resolving the long-standing debate in the field concerning 
whether the subjective effects of psychedelics are necessary for their therapeutic effects 
(Majić et al., 2015). Although our group is actively investigating the psychoplastogenic 
properties of non-hallucinogenic analogs of psychedelics, others have reported the 
therapeutic potential of safer structural and functional analogs of ketamine (Moskal et al., 
2017; Yang et al., 2015; Zanos et al., 2016).
Our data demonstrate that classical psychedelics from several distinct chemical classes are 
capable of robustly promoting the growth of both neurites and dendritic spines in vitro, in 
vivo, and across species. Importantly, our studies highlight the similarities between the 
effects of ketamine and those of classical serotonergic psychedelics, supporting the 
hypothesis that the clinical antidepressant and anxiolytic effects of these molecules might 
result from their ability to promote structural and functional plasticity in prefrontal cortical 
neurons. We have demonstrated that the plasticity-promoting properties of psychedelics 
require TrkB, mTOR, and 5-HT2A signaling, suggesting that these key signaling hubs may 
serve as potential targets for the development of psychoplastogens, fast-acting 
antidepressants, and anxiolytics. Taken together, our results suggest that psychedelics may 
be used as lead structures to identify next-generation neurotherapeutics with improved 
efficacy and safety profiles.
EXPERIMENTAL PROCEDURES
Drugs
For in vitro studies, all compounds were dissolved in DMSO and diluted 1:1,000, with the 
exception that BDNF was dissolved in water. Cells were treated with DMT at a final 
concentration of 90 μM (0.1% DMSO), whereas all other compounds were used at 10 μM 
(0.1% DMSO) unless noted otherwise. For in vivo studies, DMT or ketamine was dissolved 
in sterile 0.9% saline and administered intraperitoneally at a dose of 10 mg/kg and an 
injection volume of 1 mL/kg.
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Animals
Sprague-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA, 
USA). The age and sex of the animals used are noted under each individual experimental 
subheading. All experimental procedures involving animals were approved by the University 
of California, Davis Institutional Animal Care and Use Committee (IACUC) and adhered to 
the principles described in the NIH Guide for the Care and Use of Laboratory Animals. The 
University of California, Davis is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC) and has an Animal 
Welfare Assurance number (A3433-01) on file with the Office of Laboratory Animal 
Welfare (OLAW).
Cell Culture
Primary cortical cultures were prepared using tissue from embryonic day 18 (E18) Sprague-
Dawley rats. Cells were plated at various densities on poly-D-lysine-coated plates depending 
on the specific experiment (Supplemental Experimental Procedures). Plating medium 
consisted of 10% heat-inactivated fetal bovine serum (FBS) (Life Technologies), 1% 
penicillin-streptomycin (Life Technologies), and 0.5 mM glutamine (Life Technologies) in 
Neurobasal (Life Technologies). After 15–24 hr, the medium was removed and exchanged 
for replacement medium containing 1 × B27 supplement (Life Technologies), 1% penicillin-
streptomycin, 0.5 mM glutamine, 12.5 μM glutamate, and Neuro-basal. After 96 hr, 50% of 
the medium was removed and replaced with feed medium containing 1 × B27 supplement, 
1% penicillin-streptomycin, and 0.5 mM glutamine. Once per week, until the cultures had 
reached sufficient maturity for experiments, 50% of the culture medium was removed and 
replaced with feed medium, with an additional 20% by volume being added to account for 
evaporation. For experiments using antagonists or inhibitors, cells were pretreated with 
ANA-12 (10 μM), rapamycin (100 nM), and ketanserin (100 μM) for 10 min prior to 
addition of test compounds unless otherwise noted. The final DMSO concentration of these 
experiments was 0.2%. The neurons used in each cellular experiment were taken from at 
least two different treatment wells, and the wells were randomized to account for plate 
effects. All of the cellular experiments were replicated on at least two occasions by two or 
more experimenters.
Statistical Analysis
Appropriate samples sizes were estimated based on our previous experiences performing 
similar experiments. Data are represented as mean ± SEM. Statistical analyses were 
performed using GraphPad Prism (version 7.0a). For analyses involving comparison of three 
or more groups, a one-way analysis of variance (Dunnett’s post hoc test) was utilized. No 
statistics were calculated for the individual points of the Sholl plots. Instead, statistical 
analyses were performed on the aggregate data (i.e., the area under the curve of the Sholl 
plot). Probability distributions from electrophysiology experiments were compared using a 
Kolmogorov-Smirnov test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 
compared with vehicle control or vehicle + antagonist.
Ly et al. Page 11
Cell Rep. Author manuscript; available in PMC 2018 August 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Serotonergic psychedelics increase neuritogenesis, spinogenesis, and 
synaptogenesis
• Psychedelics promote plasticity via an evolutionarily conserved mechanism
• TrkB, mTOR, and 5-HT2A signaling underlie psychedelic-induced plasticity
• Noribogaine, but not ibogaine, is capable of promoting structural neural 
plasticity
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Figure 1. Psychedelics Promote Neuritogenesis both In Vitro and In Vivo
(A) Chemical structures of psychedelics.
(B) Representative tracings of cortical neurons (DIV6) treated with compounds.
(C) Sholl analysis demonstrates that psychedelics increase dendritic arbor complexity (n = 
39–41 neurons).
(D) Area under the curve (AUC) of the Sholl plots in (C).
(E) Maximum number of crossings (Nmax) of the Sholl plots in (C).
(F–I) Cortical neurons treated with psychedelics display an increase in the number of 
branches (F), the number of primary dendrites (G), and the total length of the dendritic arbor 
(H) but not the length of the longest dendrite (I).
(J and K) Class I neurons from Drosophila larvae treated with psychedelics during the first 
instar display increased branching (J) but not total length of the dendritic arbor (K) (n = 3 
neurons).
(L) Representative images of neurons from (J) and (K).
(M and N) Class I neurons from Drosophila larvae treated with psychedelics during the third 
instar display increased branching (M) but not total length of the dendritic arbor (N) (n = 3 
neurons).
(O) Representative images from (M) and (N).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as compared to vehicle control 
(VEH). Scale bars, 30 μm. Data are represented as mean ± SEM. See also Figures S1–S5.
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Figure 2. Psychedelics Promote Spinogenesis, Synaptogenesis, and Functional Plasticity
(A) Representative images of cortical neurons (DIV19) treated with compounds for 24 hr, 
demonstrating that psychedelics increase the number of dendritic spines (blue, MAP2; 
orange, F-actin).
(B) Quantification of spine density (n = 56–65 neurons).
(C) Relative proportions of spine types following treatment of cortical cultures with 
psychedelics (n = 16–21 neurons).
(D) Representative images of cortical neurons (DIV19) treated for 24 hr, demonstrating that 
psychedelics increase synaptogenesis (green, VGLUT1; magenta, PSD-95; yellow, MAP2). 
White areas in the VGLUT1 + PSD-95 images indicate colocalization of pre- and 
postsynaptic makers and are indicated by gray arrows.
(E–H) Quantification of synapse density (E), synapse size (F), presynaptic density 
(VGLUT1) (G), and postsynaptic density (PSD-95) (H) following 24-hr treatment of cortical 
neurons (DIV19) (n = 39–42 neurons).
(I) Representative images of Golgi-Cox-stained pyramidal neurons from the PFC of rats 24 
hr after receiving a 10 mg/kg dose of DMT.
(J) Quantification of spines from (I), demonstrating that DMT (10 mg/kg) increases 
spinogenesis in vivo to a comparable extent as ketamine (10 mg/kg) (n = 11–17 neurons).
(K and L) Whole-cell voltage-clamp recordings of layer V pyramidal neurons from slices 
obtained 24 hr after DMT treatment (10 mg/kg and 1 mg/kg) demonstrate that DMT 
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increases both spontaneous excitatory postsynaptic current (sEPSC) frequency (K) and 
amplitude (L) (n = 11–38 neurons from 3 animals).
(M) Representative traces for the 10 mg/kg experiments quantified in (K) and (L).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as compared to vehicle control 
(VEH). Data are represented as mean ± SEM. See also Figure S6.
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Figure 3. Psychedelics and BDNF Promote Neuritogenesis via a Related Mechanism
(A–C) Dose response of recombinant BDNF on neuritogenesis. AUC of the Sholl plots (A), 
Nmax of the Sholl plots (B), and total number of branches (C) of treated cortical neurons (n = 
11–12 neurons per treatment, DIV6) indicate that the highest concentration of BDNF (50 
ng/mL) is more effective at promoting neuritogenesis than lower concentrations (5.0 and 0.5 
ng/mL).
(D) Sholl analysis (n = 5–10 neurons) demonstrating that DOI (10 μM) increases 
neuritogenesis to a comparable extent as recombinant BDNF (50 ng/mL). A combination of 
DOI (10 μM) and BDNF (50 ng/mL) did not have any additive or synergistic effects.
(E) AUC of the Sholl plots in (D).
(F) Nmax of the Sholl plots in (D).
(G and H) Cultured cortical neurons (DIV18) were treated with compounds for 24 hr, and 
then BDNF gene (G) and protein (H) expression was assessed via ddPCR (n = 4) and ELISA 
(n = 3–4), respectively.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as compared to vehicle control 
(VEH). Data are represented as mean ± SEM.
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Figure 4. Psychedelic-Induced Changes in Neuronal Structure Are Mediated by TrkB
(A–D) The effects of psychedelics on dendritic arbor complexity are blocked by ANA-12, a 
selective inhibitor of TrkB, as measured by Sholl analysis of cultured cortical neurons (A) 
(DIV6). Compound-induced increases in the AUC of the Sholl plots (B), the Nmax of the 
Sholl plots (C), and the number of dendritic branches (D) are completely blocked by 
ANA-12 (n = 8–10 neurons).
(E) The spinogenesis-promoting properties of psychedelics are blocked by ANA-12 (n = 19–
21 neurons, DIV19).
(F) Control experiment demonstrating that ANA-12 blocks the effects of BDNF on 
neuritogenesis (n = 11–15 neurons).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as compared to vehicle control (VEH) 
or vehicle + antagonist. Data are represented as mean ± SEM.
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Figure 5. Psychedelic-Induced Changes in Neuronal Structure Are Mediated by mTOR
(A–D) The effects of psychedelics on dendritic arbor complexity are blocked by rapamycin, 
an inhibitor of mTOR, as measured by Sholl analysis of cultured cortical neurons (A) 
(DIV6). Compound-induced increases in the AUC of the Sholl plots (B), the Nmax of the 
Sholl plots (C), and the number of dendritic branches (D) are completely blocked by 
rapamycin (n = 9–12 neurons).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as compared to vehicle control (VEH) 
or vehicle + antagonist. Data are represented as mean ± SEM.
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Figure 6. The 5-HT2A Receptor Mediates the Effects of Psychedelics on Structural Plasticity
(A) Rat embryonic cortical neurons express 5-HT2A receptors at both DIV6 and DIV19 
(scale bar, 10 μm).
(B) The effects of psychedelics on increasing dendritic arbor complexity are blocked by co-
treating with ketanserin, a selective antagonist of 5-HT2A receptors, as measured by Sholl 
analysis of cultured cortical neurons (DIV6).
(C–E) Compound-induced increases in the AUC of the Sholl plots (C), the Nmax of the Sholl 
plots (D), and the number of dendritic branches (E) are completely blocked by ketanserin (n 
= 10–11 neurons, DIV6).
(F) The spinogenesis-promoting properties of psychedelics are blocked by ketanserin (n = 
19–20 neurons, DIV19).
(G) Ketanserin also blocks the increased Nmax induced by psilocin, noribogaine, and 
MDMA.
(H) Ketanserin dose-dependently blocks the psychoplastogenic effects of 10 nM LSD (n = 
9–38 neurons, DIV6).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, as compared to vehicle control (VEH) 
or vehicle + antagonist. Data are represented as mean ± SEM.
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